Is OMER or PCRX more profitable?

Pacira BioSciences has a net margin of 0.70% compared to Omeros' net margin of 0.00%. Pacira BioSciences' return on equity of 10.24% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -102.16% 64.87% Pacira BioSciences 0.70% 10.24% 5.47%

Pacira BioSciences (PCRX) Competitors

$25.78 +0.43 (+1.68%)

As of 03:49 PM Eastern

Compare

PCRX vs. SUPN, NKTR, PRGO, OMER, and ASMB

Should you buy Pacira BioSciences stock or one of its competitors? MarketBeat compares Pacira BioSciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pacira BioSciences include Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR), Perrigo (PRGO), Omeros (OMER), and Assembly Biosciences (ASMB). These companies are all part of the "pharmaceuticals" industry.

How does Pacira BioSciences compare to Supernus Pharmaceuticals?

Pacira BioSciences (NASDAQ:PCRX) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

Pacira BioSciences has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$726.41M	1.39	$7.03M	$0.12	213.25
Supernus Pharmaceuticals	$718.95M	3.86	-$38.55M	-$0.51	N/A

Pacira BioSciences has a net margin of 0.70% compared to Supernus Pharmaceuticals' net margin of -3.74%. Supernus Pharmaceuticals' return on equity of 13.07% beat Pacira BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	0.70%	10.24%	5.47%
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%

99.7% of Pacira BioSciences shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Pacira BioSciences has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market.

In the previous week, Pacira BioSciences' average media sentiment score of 0.00 equaled Supernus Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Pacira BioSciences	Neutral
Supernus Pharmaceuticals	Neutral

Pacira BioSciences presently has a consensus target price of $29.40, suggesting a potential upside of 14.89%. Supernus Pharmaceuticals has a consensus target price of $62.83, suggesting a potential upside of 31.56%. Given Supernus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Supernus Pharmaceuticals is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Supernus Pharmaceuticals beats Pacira BioSciences on 8 of the 14 factors compared between the two stocks.

How does Pacira BioSciences compare to Nektar Therapeutics?

Pacira BioSciences (NASDAQ:PCRX) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

Pacira BioSciences has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$726.41M	1.39	$7.03M	$0.12	213.25
Nektar Therapeutics	$55.23M	41.62	-$164.08M	-$8.42	N/A

Pacira BioSciences has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

99.7% of Pacira BioSciences shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Pacira BioSciences has a net margin of 0.70% compared to Nektar Therapeutics' net margin of -284.18%. Pacira BioSciences' return on equity of 10.24% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	0.70%	10.24%	5.47%
Nektar Therapeutics	-284.18%	-85.40%	-39.99%

Pacira BioSciences currently has a consensus price target of $29.40, suggesting a potential upside of 14.89%. Nektar Therapeutics has a consensus price target of $149.63, suggesting a potential upside of 119.94%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Nektar Therapeutics is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Nektar Therapeutics had 3 more articles in the media than Pacira BioSciences. MarketBeat recorded 3 mentions for Nektar Therapeutics and 0 mentions for Pacira BioSciences. Nektar Therapeutics' average media sentiment score of 0.51 beat Pacira BioSciences' score of 0.00 indicating that Nektar Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Pacira BioSciences	Neutral
Nektar Therapeutics	Positive

Summary

Pacira BioSciences beats Nektar Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Pacira BioSciences compare to Perrigo?

Perrigo (NYSE:PRGO) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

95.9% of Perrigo shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 0.4% of Perrigo shares are held by insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Perrigo has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

Perrigo presently has a consensus target price of $19.33, suggesting a potential upside of 86.71%. Pacira BioSciences has a consensus target price of $29.40, suggesting a potential upside of 14.89%. Given Perrigo's higher possible upside, equities analysts clearly believe Perrigo is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Pacira BioSciences has a net margin of 0.70% compared to Perrigo's net margin of -43.50%. Pacira BioSciences' return on equity of 10.24% beat Perrigo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-43.50%	9.96%	3.90%
Pacira BioSciences	0.70%	10.24%	5.47%

In the previous week, Perrigo had 2 more articles in the media than Pacira BioSciences. MarketBeat recorded 2 mentions for Perrigo and 0 mentions for Pacira BioSciences. Perrigo's average media sentiment score of 0.00 equaled Pacira BioSciences'average media sentiment score.

Company	Overall Sentiment
Perrigo	Neutral
Pacira BioSciences	Neutral

Pacira BioSciences has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.34	-$1.43B	-$13.10	N/A
Pacira BioSciences	$726.41M	1.39	$7.03M	$0.12	213.25

Summary

Pacira BioSciences beats Perrigo on 11 of the 15 factors compared between the two stocks.

How does Pacira BioSciences compare to Omeros?

Omeros (NASDAQ:OMER) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Omeros has a beta of 2.55, meaning that its share price is 155% more volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

48.8% of Omeros shares are owned by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are owned by institutional investors. 10.5% of Omeros shares are owned by insiders. Comparatively, 6.4% of Pacira BioSciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Pacira BioSciences has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$0.70	13.41
Pacira BioSciences	$726.41M	1.39	$7.03M	$0.12	213.25

In the previous week, Omeros had 12 more articles in the media than Pacira BioSciences. MarketBeat recorded 12 mentions for Omeros and 0 mentions for Pacira BioSciences. Omeros' average media sentiment score of 0.40 beat Pacira BioSciences' score of 0.00 indicating that Omeros is being referred to more favorably in the media.

Company	Overall Sentiment
Omeros	Neutral
Pacira BioSciences	Neutral

Omeros currently has a consensus target price of $38.00, indicating a potential upside of 304.77%. Pacira BioSciences has a consensus target price of $29.40, indicating a potential upside of 14.89%. Given Omeros' stronger consensus rating and higher possible upside, equities research analysts plainly believe Omeros is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Pacira BioSciences has a net margin of 0.70% compared to Omeros' net margin of 0.00%. Pacira BioSciences' return on equity of 10.24% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Pacira BioSciences	0.70%	10.24%	5.47%

Summary

Omeros beats Pacira BioSciences on 9 of the 16 factors compared between the two stocks.

How does Pacira BioSciences compare to Assembly Biosciences?

Pacira BioSciences (NASDAQ:PCRX) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Pacira BioSciences has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$726.41M	1.39	$7.03M	$0.12	213.25
Assembly Biosciences	$72.30M	5.77	-$6.12M	-$0.11	N/A

99.7% of Pacira BioSciences shares are held by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by insiders. Comparatively, 3.5% of Assembly Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Pacira BioSciences currently has a consensus price target of $29.40, suggesting a potential upside of 14.89%. Assembly Biosciences has a consensus price target of $44.00, suggesting a potential upside of 67.68%. Given Assembly Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Assembly Biosciences is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Assembly Biosciences had 2 more articles in the media than Pacira BioSciences. MarketBeat recorded 2 mentions for Assembly Biosciences and 0 mentions for Pacira BioSciences. Assembly Biosciences' average media sentiment score of 1.77 beat Pacira BioSciences' score of 0.00 indicating that Assembly Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Pacira BioSciences	Neutral
Assembly Biosciences	Very Positive

Pacira BioSciences has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

Pacira BioSciences has a net margin of 0.70% compared to Assembly Biosciences' net margin of -8.98%. Pacira BioSciences' return on equity of 10.24% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	0.70%	10.24%	5.47%
Assembly Biosciences	-8.98%	-4.21%	-3.14%

Summary

Pacira BioSciences beats Assembly Biosciences on 9 of the 16 factors compared between the two stocks.

Get Pacira BioSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PCRX vs. The Competition

Export

Metric	Pacira BioSciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.01B	$3.65B	$6.80B	$12.44B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	213.34	20.66	27.00	24.19
Price / Sales	1.39	322.67	518.66	94.29
Price / Cash	6.64	60.31	26.68	47.25
Price / Book	1.59	8.17	10.68	6.26
Net Income	$7.03M	$23.81M	$3.59B	$331.52M
7 Day Performance	2.32%	-1.53%	-0.19%	-1.19%
1 Month Performance	14.60%	2.21%	1.93%	-1.35%
1 Year Performance	15.43%	44.90%	25.24%	18.74%

Pacira BioSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PCRX Pacira BioSciences	1.711 of 5 stars	$25.78 +1.7%	$29.40 +14.1%	+17.4%	$1.01B	$726.41M	214.31	720
SUPN Supernus Pharmaceuticals	3.1356 of 5 stars	$47.35 -2.3%	$62.83 +32.7%	+46.6%	$2.81B	$718.95M	N/A	580
NKTR Nektar Therapeutics	2.534 of 5 stars	$68.32 -2.9%	$149.63 +119.0%	+160.0%	$2.38B	$55.23M	N/A	220
PRGO Perrigo	3.1897 of 5 stars	$10.17 -0.5%	$19.33 +90.2%	-60.7%	$1.41B	$4.25B	N/A	8,100
OMER Omeros	3.8368 of 5 stars	$10.01 -2.6%	$38.00 +279.6%	+186.6%	$744.02M	N/A	14.30	210	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PCRX) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pacira BioSciences (PCRX) Competitors

PCRX vs. SUPN, NKTR, PRGO, OMER, and ASMB

How does Pacira BioSciences compare to Supernus Pharmaceuticals?

Summary

How does Pacira BioSciences compare to Nektar Therapeutics?

Summary

How does Pacira BioSciences compare to Perrigo?

Summary

How does Pacira BioSciences compare to Omeros?

Summary

How does Pacira BioSciences compare to Assembly Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCRX vs. The Competition

Pacira BioSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pacira BioSciences (PCRX) Competitors

PCRX vs. SUPN, NKTR, PRGO, OMER, and ASMB

How does Pacira BioSciences compare to Supernus Pharmaceuticals?

Which has higher earnings & valuation, PCRX or SUPN?

Is PCRX or SUPN more profitable?

Do insiders and institutionals have more ownership in PCRX or SUPN?

Which has more volatility and risk, PCRX or SUPN?

Does the media favor PCRX or SUPN?

Do analysts prefer PCRX or SUPN?

Summary

How does Pacira BioSciences compare to Nektar Therapeutics?

Which has preferable earnings & valuation, PCRX or NKTR?

Which has more volatility and risk, PCRX or NKTR?

Do insiders and institutionals hold more shares of PCRX or NKTR?

Is PCRX or NKTR more profitable?

Do analysts rate PCRX or NKTR?

Does the media favor PCRX or NKTR?

Summary

How does Pacira BioSciences compare to Perrigo?

Do insiders and institutionals hold more shares of PRGO or PCRX?

Which has more risk and volatility, PRGO or PCRX?

Do analysts rate PRGO or PCRX?

Is PRGO or PCRX more profitable?

Does the media refer more to PRGO or PCRX?

Which has better earnings and valuation, PRGO or PCRX?

Summary

How does Pacira BioSciences compare to Omeros?

Which has more risk & volatility, OMER or PCRX?

Do insiders & institutionals have more ownership in OMER or PCRX?

Which has preferable valuation & earnings, OMER or PCRX?

Does the media refer more to OMER or PCRX?

Do analysts recommend OMER or PCRX?

Is OMER or PCRX more profitable?

Summary

How does Pacira BioSciences compare to Assembly Biosciences?

Which has preferable valuation and earnings, PCRX or ASMB?

Do insiders and institutionals hold more shares of PCRX or ASMB?

Do analysts recommend PCRX or ASMB?

Does the media prefer PCRX or ASMB?

Which has more risk and volatility, PCRX or ASMB?

Is PCRX or ASMB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCRX vs. The Competition

Pacira BioSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools